|
|
Vaccine Detail
|
Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2 |
| Vaccine Information |
- Vaccine Name: Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007006
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Description: This is for Brain Cancer (NCT02149225). A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient's own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing (NCIT_C116332).
|
| Host Response |
|
|
| References |
NCIT_C116332: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116332]
NCT02149225: [https://clinicaltrials.gov/show/NCT02149225/]
|
|
